BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27109742)

  • 1. Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Wang JY; Li YJ
    Oncol Rep; 2016 Jun; 35(6):3659-68. PubMed ID: 27109742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
    Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium azulene sulfonate reverses multidrug resistance in K562/A02 cells.
    Wang Z; Zhou N; Zhao J; Zhang X
    Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):105-110. PubMed ID: 31880526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel bis-benzylisoquinoline PY35 reverses P-glycoprotein-mediated multidrug resistance.
    Cao Z; Wright M; Cheng J; Huang X; Liu L; Wu L; Yang P
    Oncol Rep; 2014 Sep; 32(3):1211-7. PubMed ID: 25017650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
    Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
    Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Reversal of multidrug resistance by lomerizine in K562/ADM cells].
    Zhu HJ; Wu YL; Liu GQ
    Yao Xue Xue Bao; 2004 May; 39(5):333-7. PubMed ID: 15338873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression.
    Pan J; Miao D; Chen L
    Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Ji BS; He L; Liu GQ
    Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts.
    Tazzari PL; Cappellini A; Ricci F; Evangelisti C; Papa V; Grafone T; Martinelli G; Conte R; Cocco L; McCubrey JA; Martelli AM
    Leukemia; 2007 Mar; 21(3):427-38. PubMed ID: 17215852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells.
    Ji BS; He L
    J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen reduces P-gp-mediated multidrug resistance via inhibiting the PI3K/Akt signaling pathway in ER-negative human gastric cancer cells.
    Mao Z; Zhou J; Luan J; Sheng W; Shen X; Dong X
    Biomed Pharmacother; 2014 Mar; 68(2):179-83. PubMed ID: 24184201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells.
    Chen JR; Jia XH; Wang H; Yi YJ; Li YJ
    Oncol Rep; 2017 May; 37(5):2735-2742. PubMed ID: 28358418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol Increases Anti-Proliferative Activity of Bestatin Through Downregulating P-Glycoprotein Expression Via Inhibiting PI3K/Akt/mTOR Pathway in K562/ADR Cells.
    Wang L; Wang C; Jia Y; Liu Z; Shu X; Liu K
    J Cell Biochem; 2016 May; 117(5):1233-9. PubMed ID: 26460589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
    Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
    Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reversal of mdrl gene-dependent multidrug resistance in multidrug resistance human leukemia cell line K562/ADM using short hairpin RNA expression vectors].
    Gan HZ; Zhang GZ; Lu ZX; Pu LS; Yang SJ; Gao S; Zheng DM
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):383-7. PubMed ID: 17939403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.